Literature DB >> 25210559

Complications of intravesical bacillus calmette-guérin.

Liam C Macleod1, Tin C Ngo2, Mark L Gonzalgo2.   

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) is an important treatment for the management of non-muscle invasive bladder cancer because of its proven efficacy and favourable safety profile. The most common complications associated with BCG treatment are relatively minor. They include urinary frequency, cystitis, fever, and hematuria. Although serious complications are rare, patients can develop severe, life-threatening sepsis with disseminated mycobacterial infection. We report a rare case of periurethral diverticulum formation after intravesical BCG and review the literature on the potential complications of this treatment modality.

Entities:  

Year:  2014        PMID: 25210559      PMCID: PMC4137021          DOI: 10.5489/cuaj.1411

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  54 in total

1.  Diagnosis please. Case 9: mycotic pseudoaneurysm of the abdominal aorta in association with mycobacterial psoas abscess--a complication of BCG therapy.

Authors:  J M LaBerge; R K Kerlan; L M Reilly; T A Chuter
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  Granulomatous hepatitis and hemophagocytic syndrome after bacillus Calmette-Guerin bladder instillation.

Authors:  Thierry Thevenot; Vincent Di Martino; Aurélie Lagrange; Tony Petrella; Jean-François Faucher; Jean Fontan; Mélanie Terebus; Jean-Philippe Miguet; Solange Bresson-Hadni
Journal:  Gastroenterol Clin Biol       Date:  2006-03

3.  Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy.

Authors:  Hattori Yusuke; Hara Yoshinori; Matsuura Kenichi; Hasegawa Akio
Journal:  Int J Urol       Date:  2006-10       Impact factor: 3.369

4.  Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.

Authors:  O Onur; R Celiker
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

5.  Granulomatous hepatitis after intravesical BCG treatment for bladder cancer.

Authors:  Osman Ersoy; Rasit Aran; Musa Aydinli; Ozlem Yonem; Ozgur Harmanci; Bulent Akdogan; Ahmet Pinar; Cenk Sokmensuer; Yusuf Bayraktar
Journal:  Indian J Gastroenterol       Date:  2006 Sep-Oct

Review 6.  Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis?

Authors:  Qingping Yao; Xiangqian Su; Roy D Altman
Journal:  Semin Arthritis Rheum       Date:  2009-02-13       Impact factor: 5.532

7.  Clinical and immunologic studies of disseminated BCG infection.

Authors:  S A Rosenberg; C Seipp; H F Sears
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

8.  Pulmonary granulomata. A complication of intravesical administration of bacillus Calmette-Guerin for superficial bladder carcinoma.

Authors:  R L Smith; R F Alexander; C P Aranda
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

Review 9.  Osteoarticular side effects of BCG therapy.

Authors:  Gaëlle Clavel; Franck Grados; Pascal Lefauveau; Patrice Fardellone
Journal:  Joint Bone Spine       Date:  2005-03-24       Impact factor: 4.929

Review 10.  Renal complications of intravesical bacillus Calmette-Guérin therapy.

Authors:  A Modesto; L Marty; J M Suc; D Kleinknecht; J F de Frémont; T Marsepoil; P Veyssier
Journal:  Am J Nephrol       Date:  1991       Impact factor: 3.754

View more
  10 in total

1.  Diagnosing the Treatment.

Authors:  Sarah A McGuffin; Robert L Trowbridge; Ann M O'Hare; Andrew P Olson
Journal:  J Hosp Med       Date:  2018-06-27       Impact factor: 2.960

2.  Mycotic aneurysm formation after bacillus Calmette-Guérin instillation for recurrent bladder cancer.

Authors:  Sagar Rohailla; Abhijat Kitchlu; Mark Wheatcroft; Fahad Razak
Journal:  CMAJ       Date:  2018-04-16       Impact factor: 8.262

Review 3.  Immune checkpoint blockade therapy for bladder cancer treatment.

Authors:  Jayoung Kim
Journal:  Investig Clin Urol       Date:  2016-05-26

4.  Formulation and characterization of EGCG for the treatment of superficial bladder cancer.

Authors:  Katarzyna Dettlaff; Maciej Stawny; Magdalena Ogrodowczyk; Anna Jelińska; Waldemar Bednarski; Dorota Wątróbska-Świetlikowska; Rick W Keck; Omar A Khan; Ibrahim H Mostafa; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2017-06-14       Impact factor: 4.101

Review 5.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

6.  Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer.

Authors:  Karan Seegobin; Satish Maharaj; Cherisse Baldeo; Carmen Isache; Bharatsinh Gharia; Lara Zuberi
Journal:  IDCases       Date:  2017-09-28

7.  Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.

Authors:  Kai Sun; Di Wang; Gang Wu; Jian Ma; Tianqi Wang; Jitao Wu; Jipeng Wang
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

8.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.

Authors:  Matthew D Galsky; Arjun V Balar; Peter C Black; Matthew T Campbell; Gail S Dykstra; Petros Grivas; Shilpa Gupta; Christoper J Hoimes; Lidia P Lopez; Joshua J Meeks; Elizabeth R Plimack; Jonathan E Rosenberg; Neal Shore; Gary D Steinberg; Ashish M Kamat
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

Review 9.  Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.

Authors:  Karel Decaestecker; Willem Oosterlinck
Journal:  Res Rep Urol       Date:  2015-10-23

10.  Tuberculous Psoas Abscess and Worsening Vascular Aneurysm; All from Bacillus Calmette-Guerin (BCG) Therapy?

Authors:  Emmanuel Okon; Janelle Stearns; Arun Kumar Durgam
Journal:  Am J Case Rep       Date:  2017-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.